Dose for Deep Neuromuscular Blockade Deciding Factor of Neuromuscular Blocker Dose for Deep Neuromuscular Blockade
Find Out the Deciding Factor of Neuromuscular Blocker Dose for Deep Neuromuscular Blockade
1 other identifier
observational
90
0 countries
N/A
Brief Summary
Find out the deciding factor(total body weight, corrected body weight, ideal body weight, fat-free mass, body mass index, skeletal muscle mass, body fat) of neuromuscular blocker dose for deep neuromuscular blockade.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2021
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 23, 2020
CompletedFirst Posted
Study publicly available on registry
December 29, 2020
CompletedStudy Start
First participant enrolled
January 10, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
July 30, 2021
CompletedDecember 30, 2020
December 1, 2020
7 months
December 23, 2020
December 28, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
the highest correlation coefficient
the relationship of rocuronium for deep neuromuscular blockade and 8 factors (corrected body weight, ideal body weight, lean body weight, fat-free mass, body mass index, skeletal muscle mass, body fat)
preoperative 1 days to postoperative 1 days
Secondary Outcomes (3)
onset time of rocuronium
preoperative 1 days to postoperative 1 days
Time to deep neuromuscular blockade
preoperative 1 days to postoperative 1 days
Recovery time
preoperative 1 days to postoperative 1 days
Study Arms (1)
deep neuromuscular blockade
patients who underwent surgery with deep neuromuscular blockade
Interventions
Eligibility Criteria
Patients aged 20-80 and American Society of Anesthesiology Physical Grade (ASA) I-II, who undergo laparoscopic surgery for at least 2 hours under general anesthesia.
You may qualify if:
- patients aged 20-80 and American Society of Anesthesiology Physical Grade (ASA) I-II, who undergo laparoscopic surgery for at least 2 hours under general anesthesia
You may not qualify if:
- kidney disease (GFR\<60)
- allergy to study drugs
- decline participation
- side effect of propofol and remifentanil
- when anesthesia does not maintain the level of alertness (BIS) below 60 even when the anesthetic dose is increased, or when hemodynamic instability such as bradycardia and hypotension appears
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Choi YJ, Hee Kim Y, Bae GE, Yu JH, Yoon SZ, Kang HW, Lee KS, Kim JH, Lee YS. Relationship between the muscle relaxation effect and body muscle mass measured using bioelectrical impedance analysis: A nonrandomized controlled trial. J Int Med Res. 2019 Apr;47(4):1521-1532. doi: 10.1177/0300060518822197. Epub 2019 Feb 5.
PMID: 30719949BACKGROUND
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principal investigator
Study Record Dates
First Submitted
December 23, 2020
First Posted
December 29, 2020
Study Start
January 10, 2021
Primary Completion
July 30, 2021
Study Completion
July 30, 2021
Last Updated
December 30, 2020
Record last verified: 2020-12